Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
China · Delayed Price · Currency is CNY 34.09
+0.02 (0.06%)
Feb 4, 2026, 1:15 PM CST
SHA:600976 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 |
Operating Revenue | 3,154 | 3,484 | 4,190 | 3,623 | 3,292 | 2,445 |
Other Revenue | 21.13 | 21.13 | 23.59 | 17.41 | 7.8 | 11.32 |
| 3,176 | 3,505 | 4,213 | 3,641 | 3,299 | 2,456 | |
Revenue Growth (YoY) | -20.15% | -16.81% | 15.72% | 10.35% | 34.34% | 9.70% |
Cost of Revenue | 1,234 | 1,835 | 2,279 | 2,067 | 1,882 | 1,460 |
Gross Profit | 1,941 | 1,670 | 1,934 | 1,574 | 1,417 | 996.15 |
Selling, General & Admin | 1,618 | 1,418 | 1,515 | 1,203 | 1,129 | 889.85 |
Research & Development | 97.37 | 79.49 | 74.05 | 73.19 | 52.61 | 37.4 |
Other Operating Expenses | 47.65 | 15.79 | 29.03 | 24.52 | 22.96 | 14.28 |
Operating Expenses | 1,808 | 1,558 | 1,621 | 1,311 | 1,210 | 942.47 |
Operating Income | 133.87 | 111.6 | 313.12 | 262.77 | 207.46 | 53.69 |
Interest Expense | -11.63 | -12.93 | -3.7 | -4.81 | -8.71 | -0.55 |
Interest & Investment Income | 156.17 | 228.44 | 235.04 | 167.26 | 127.46 | 104.91 |
Other Non Operating Income (Expenses) | 4.07 | -2.33 | -7.51 | -21.95 | -4.77 | -0.39 |
EBT Excluding Unusual Items | 282.48 | 324.77 | 536.94 | 403.27 | 321.44 | 157.66 |
Gain (Loss) on Sale of Investments | 28.83 | 28.4 | 6.18 | -12.11 | -2.46 | -1.6 |
Gain (Loss) on Sale of Assets | -2.89 | -2.67 | 0.16 | -1.14 | -0.93 | -0.22 |
Asset Writedown | -0.42 | -0.42 | -11.39 | -9.61 | -0.09 | -1.38 |
Other Unusual Items | 42.53 | 42.53 | 39.21 | 57.53 | 23.5 | 3.16 |
Pretax Income | 350.53 | 392.62 | 571.09 | 437.94 | 341.45 | 157.61 |
Income Tax Expense | 18.77 | 24.87 | 47.86 | 31.93 | 35.51 | 8.92 |
Earnings From Continuing Operations | 331.77 | 367.75 | 523.23 | 406.01 | 305.94 | 148.69 |
Minority Interest in Earnings | -5.47 | -5.57 | -1.78 | 2.07 | -0.68 | -0.9 |
Net Income | 326.3 | 362.18 | 521.46 | 408.08 | 305.26 | 147.79 |
Net Income to Common | 326.3 | 362.18 | 521.46 | 408.08 | 305.26 | 147.79 |
Net Income Growth | -23.75% | -30.55% | 27.78% | 33.68% | 106.55% | 61.53% |
Shares Outstanding (Basic) | 151 | 152 | 153 | 152 | 152 | 154 |
Shares Outstanding (Diluted) | 151 | 152 | 153 | 152 | 152 | 154 |
Shares Change (YoY) | -1.31% | -0.49% | 0.43% | 0.26% | -1.35% | 0.96% |
EPS (Basic) | 2.16 | 2.38 | 3.41 | 2.68 | 2.01 | 0.96 |
EPS (Diluted) | 2.16 | 2.38 | 3.41 | 2.68 | 2.01 | 0.96 |
EPS Growth | -22.74% | -30.20% | 27.24% | 33.33% | 109.38% | 60.00% |
Free Cash Flow | 160.45 | 113.98 | 203.89 | 147.9 | 191.77 | 79.96 |
Free Cash Flow Per Share | 1.06 | 0.75 | 1.33 | 0.97 | 1.26 | 0.52 |
Dividend Per Share | 0.900 | 0.900 | 1.200 | 1.000 | 0.806 | 0.366 |
Dividend Growth | -25.00% | -25.00% | 20.00% | 24.07% | 120.22% | 83.00% |
Gross Margin | 61.13% | 47.63% | 45.91% | 43.23% | 42.96% | 40.56% |
Operating Margin | 4.22% | 3.18% | 7.43% | 7.22% | 6.29% | 2.19% |
Profit Margin | 10.27% | 10.33% | 12.38% | 11.21% | 9.25% | 6.02% |
Free Cash Flow Margin | 5.05% | 3.25% | 4.84% | 4.06% | 5.81% | 3.26% |
EBITDA | 167.93 | 145.19 | 346.1 | 294.96 | 235.92 | 74.38 |
EBITDA Margin | 5.29% | 4.14% | 8.21% | 8.10% | 7.15% | 3.03% |
D&A For EBITDA | 34.06 | 33.6 | 32.98 | 32.19 | 28.47 | 20.7 |
EBIT | 133.87 | 111.6 | 313.12 | 262.77 | 207.46 | 53.69 |
EBIT Margin | 4.22% | 3.18% | 7.43% | 7.22% | 6.29% | 2.19% |
Effective Tax Rate | 5.35% | 6.33% | 8.38% | 7.29% | 10.40% | 5.66% |
Revenue as Reported | 3,176 | 3,505 | 4,213 | 3,641 | 3,299 | 2,456 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.